Robin L Smith
CIK 1365035 · Executive Chair of the Board · last filed 2025-05-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NBS.U price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
330 SOUTH SERVICE ROAD, SUITE 120
MELVILLE, NY 11747
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MTNB | Director | — | $1.79 | — | $0 | 1 | 2025-05-02 |
| Celularity Inc (CELUW) Delisted | Director | 236,066 | $0.00 | $449 | $0 | 5 | 2023-06-16 |
| Sorrento Therapeutics, Inc. (SRNE) Delisted | Director | 135,000 | $0.00 | $68 | $90.9K | 5 | 2021-09-03 |
| CONCENTRIX SERVICESOURCE INC. (SREV) Delisted | Director | 167,975 | $1.50 | $252.0K | $85.0K | 3 | 2020-05-21 |
| SEELOS THERAPEUTICS, INC. (SEEL) Delisted | Director | — | $0.39 | — | $0 | 2 | 2020-01-07 |
| RMTI | Director | 285 | $7.00 | $2.0K | $0 | 4 | 2019-06-10 |
| Emmaus Life Sciences, Inc. (MYNDW) Delisted | Director | 211,539 | — | — | $0 | 9 | 2019-05-10 |
| Viridian Therapeutics, Inc.\DE (SGNL) Delisted | Director | 1,900 | — | — | $0 | 5 | 2017-02-07 |
| LISATA THERAPEUTICS, INC. (NBS) Delisted | Executive Chair of the Board | 347,285 | — | — | $24.8K | 11 | 2015-06-04 |
| LISATA THERAPEUTICS, INC. (NBS.WS) Delisted | Chairman of the Board and CEO | 1,659,533 | — | — | $37.7K | 32 | 2012-07-06 |
| LISATA THERAPEUTICS, INC. (NBS.U) Delisted | CEO and Chairman of the Board | 130,562 | — | — | $54.45M | 2 | 2007-10-01 |
Recent Filings · Page 6 of 10
95 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-08-01 | LISATA THERAPEUTICS, INC. (NBS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-07-21 | Viridian Therapeutics, Inc.\DE (SGNL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-07-01 | LISATA THERAPEUTICS, INC. (NBS) Delisted | Grant (A) | +2,010 | $11.1K | EDGAR |
| 2014-01-03 | LISATA THERAPEUTICS, INC. (NBS) Delisted | Grant (A) | +96,093 | $10.1K | EDGAR |
| 2013-03-07 | LISATA THERAPEUTICS, INC. (NBS) Delisted | Grant (A) | +100,000 | $53.0K | EDGAR |
| 2013-01-04 | LISATA THERAPEUTICS, INC. (NBS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-09-18 | LISATA THERAPEUTICS, INC. (NBS) Delisted | Buy (P) | +36,000 | $24.8K | EDGAR |
| 2012-08-17 | LISATA THERAPEUTICS, INC. (NBS) Delisted | Mixed | +54,000 | $0 | EDGAR |
| 2012-07-06 | LISATA THERAPEUTICS, INC. (NBS.WS) Delisted | Grant (A) | +150,000 | $78.0K | EDGAR |
| 2012-04-30 | LISATA THERAPEUTICS, INC. (NBS.WS) Delisted | Grant (A) | +24,872 | $9.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.